NEW YORK – A newly relaunched population screening project in Canada is attempting to improve identification of germline BRCA1/2 mutation carriers, and in particular, flag high-risk patients with early-stage breast or prostate cancer so doctors can given them the necessary screening and treatment that allows them to live better and longer.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.